Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1041209

registered interest
date	14/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	University Hospitals Bristol NHS Foundation Trust: Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they plan to take to lift the ban on the prescription of liothyronine (T3) by University Hospital Bristol in contradiction of the advice given by NHS England.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12791
answer	answer is ministerial correction date of answer 22/01/2019 answer text <p>NHS England is working closely with clinical commissioning groups (CCGs) on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care. The Department has not had specific discussions with NHS England or made an assessment on these issues.</p><p>CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs. CCGs set the policy which governs what hospitals and trusts implement, therefore the prescription of liothyronine at University Hospital Bristol and Musgrove Park Hospital in Taunton is a matter for those CCGs.</p><p>This guidance for CCGs on items which should not be routinely prescribed in primary care includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances,</p><p>where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. A copy of <em>Guidance – Prescribing of Liothyronine</em> is attached.</p> answering member printed Baroness Manzoor grouped question UIN HL12792 HL12793 HL12794 question first answered 22/01/2019 16:17:24 answering member 4289 label Biography information for Baroness Manzoor attachment 1 file name RMOC-Liothyronine-Guidance-v2.0-final-1.pdf title RMOC liothyronine guidance
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1041210

registered interest
date	14/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Musgrove Park Hospital: Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they plan to take to change the approach to the prescription of liothyronine (T3) being taken by Musgrove Hospital, Taunton which is in contradiction of the advice given by NHS England.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12792
answer	answer is ministerial correction date of answer 22/01/2019 answer text <p>NHS England is working closely with clinical commissioning groups (CCGs) on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care. The Department has not had specific discussions with NHS England or made an assessment on these issues.</p><p>CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs. CCGs set the policy which governs what hospitals and trusts implement, therefore the prescription of liothyronine at University Hospital Bristol and Musgrove Park Hospital in Taunton is a matter for those CCGs.</p><p>This guidance for CCGs on items which should not be routinely prescribed in primary care includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances,</p><p>where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. A copy of <em>Guidance – Prescribing of Liothyronine</em> is attached.</p> answering member printed Baroness Manzoor grouped question UIN HL12791 HL12793 HL12794 question first answered 22/01/2019 16:17:24 answering member 4289 label Biography information for Baroness Manzoor attachment 1 file name RMOC-Liothyronine-Guidance-v2.0-final-1.pdf title RMOC liothyronine guidance
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1041211

registered interest
date	14/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they have had with NHS England about the ability for doctors to follow the advice given on the prescription of liothyronine (T3) when bans on its prescription have been put in place at a local level.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12793
answer	answer is ministerial correction date of answer 22/01/2019 answer text <p>NHS England is working closely with clinical commissioning groups (CCGs) on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care. The Department has not had specific discussions with NHS England or made an assessment on these issues.</p><p>CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs. CCGs set the policy which governs what hospitals and trusts implement, therefore the prescription of liothyronine at University Hospital Bristol and Musgrove Park Hospital in Taunton is a matter for those CCGs.</p><p>This guidance for CCGs on items which should not be routinely prescribed in primary care includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances,</p><p>where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. A copy of <em>Guidance – Prescribing of Liothyronine</em> is attached.</p> answering member printed Baroness Manzoor grouped question UIN HL12791 HL12792 HL12794 question first answered 22/01/2019 16:17:24 answering member 4289 label Biography information for Baroness Manzoor attachment 1 file name RMOC-Liothyronine-Guidance-v2.0-final-1.pdf title RMOC liothyronine guidance
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1041212

registered interest
date	14/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the barriers in place to the prescription of liothyronine (T3) in England, if any; and what steps they plan to take to overcome any such barriers.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12794
answer	answer is ministerial correction date of answer 22/01/2019 answer text <p>NHS England is working closely with clinical commissioning groups (CCGs) on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care. The Department has not had specific discussions with NHS England or made an assessment on these issues.</p><p>CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs. CCGs set the policy which governs what hospitals and trusts implement, therefore the prescription of liothyronine at University Hospital Bristol and Musgrove Park Hospital in Taunton is a matter for those CCGs.</p><p>This guidance for CCGs on items which should not be routinely prescribed in primary care includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances,</p><p>where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. A copy of <em>Guidance – Prescribing of Liothyronine</em> is attached.</p> answering member printed Baroness Manzoor grouped question UIN HL12791 HL12792 HL12793 question first answered 22/01/2019 16:17:24 answering member 4289 label Biography information for Baroness Manzoor attachment 1 file name RMOC-Liothyronine-Guidance-v2.0-final-1.pdf title RMOC liothyronine guidance
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1037606

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Foreign Nationals
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many written submissions they have received as part of the review of the National Health Service (Charges to Overseas Visitors) (Amendment) Regulations 2017; how many case studies were submitted to the review where urgent care was withheld; and what assessment they have made of the number of case studies submitted where urgent care was, or may have, been incorrectly withheld.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12662
answer	answer is ministerial correction date of answer 22/01/2019 answer text <p>The Department engaged with 79 organisations as part of the process of reviewing of the National Health Service (Charges to Overseas Visitors) (Amendment) Regulations 2017 and received 57 formal responses. Of these, 22 case studies included instances where individuals were required to make advance payment for treatment that the Department has concluded was arguably, on proper analysis, immediately necessary and/or urgent.</p><p>The common issue in these cases is that clinicians have not fully taken into account the date at which those seeking treatment have been expected to leave the United Kingdom, something that national guidance is clear must be taken into consideration when making a decision as to whether or not treatment is considered urgent. To mitigate this risk and help ensure the regulations are applied as intended the Department has updated its guidance, published on 24 December 2018, and is planning further updates to relevant training material and case studies in early 2019 to ensure all relevant circumstances are considered when deciding if a treatment is to be considered immediately necessary, urgent or non-urgent.</p> answering member printed Baroness Manzoor question first answered 22/01/2019 16:03:35 answering member 4289 label Biography information for Baroness Manzoor
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1037607

registered interest
date	08/01/2019
answering body	Department for Digital, Culture, Media and Sport
answering dept id	10
answering dept short name	Digital, Culture, Media and Sport
answering dept sort name	Digital, Culture, Media and Sport
hansard heading	Gambling: Internet
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they have had with the Children’s Commissioner about mystery boxes in online games; and whether those boxes encourage online gambling by children.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12663
answer	answer is ministerial correction date of answer 17/01/2019 answer text <p>Mystery boxes in video games, also known as loot boxes do not fall under gambling law where the in-game items acquired are confined for use within the game and cannot be cashed out. However, the Government is aware of concerns that loot boxes could encourage gambling-like behaviour and longer term lead to gambling related harm, especially amongst children, and will continue to look closely at any evidence around this issue.</p><p> </p><p>In September 2018, 16 regulators from Europe and the USA, including the Gambling Commission signed a declaration which outlined common concerns around gaming and gambling. The regulators agreed to work together to monitor the characteristics of video games and social gaming and where there is potential cross-over into gambling.</p><p> </p><p>We welcomed the introduction last year by the VSC Ratings Board and PEGI of a new label for video games to warn parents where they include the opportunity to make in-games purchases such as loot boxes. Microtransactions in games—including loot boxes—are further subject to the Consumer Protection from Unfair Trading Regulations 2008 which protect against misleading or aggressive marketing.</p><p> </p><p>DCMS is working closely with the games industry, agencies such as the Video Standards Council (VSC) and others to improve online safety in games, including promoting healthy and responsible gaming. To better understand the relationship between social media and the mental health of children and young people up to 25 years old, the Chief Medical Officer will be leading a systematic review to examine all relevant international research in the area.</p><p> </p> answering member printed Lord Ashton of Hyde grouped question UIN HL12664 question first answered 17/01/2019 11:51:01 answering member 4247 label Biography information for Lord Ashton of Hyde
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1037609

registered interest
date	08/01/2019
answering body	Department for Digital, Culture, Media and Sport
answering dept id	10
answering dept short name	Digital, Culture, Media and Sport
answering dept sort name	Digital, Culture, Media and Sport
hansard heading	Gambling: Internet
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action, if any, they intend to take to prohibit the use of mystery boxes in online games.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12664
answer	answer is ministerial correction date of answer 17/01/2019 answer text <p>Mystery boxes in video games, also known as loot boxes do not fall under gambling law where the in-game items acquired are confined for use within the game and cannot be cashed out. However, the Government is aware of concerns that loot boxes could encourage gambling-like behaviour and longer term lead to gambling related harm, especially amongst children, and will continue to look closely at any evidence around this issue.</p><p> </p><p>In September 2018, 16 regulators from Europe and the USA, including the Gambling Commission signed a declaration which outlined common concerns around gaming and gambling. The regulators agreed to work together to monitor the characteristics of video games and social gaming and where there is potential cross-over into gambling.</p><p> </p><p>We welcomed the introduction last year by the VSC Ratings Board and PEGI of a new label for video games to warn parents where they include the opportunity to make in-games purchases such as loot boxes. Microtransactions in games—including loot boxes—are further subject to the Consumer Protection from Unfair Trading Regulations 2008 which protect against misleading or aggressive marketing.</p><p> </p><p>DCMS is working closely with the games industry, agencies such as the Video Standards Council (VSC) and others to improve online safety in games, including promoting healthy and responsible gaming. To better understand the relationship between social media and the mental health of children and young people up to 25 years old, the Chief Medical Officer will be leading a systematic review to examine all relevant international research in the area.</p><p> </p> answering member printed Lord Ashton of Hyde grouped question UIN HL12663 question first answered 17/01/2019 11:51:02 answering member 4247 label Biography information for Lord Ashton of Hyde
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1036969

registered interest
date	07/01/2019
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Ministry of Defence: Contracts
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the report by the National Audit Office Investigation into the British Army Recruiting Partnering Project, published on 14 December 2018, what action they are taking to improve contract (1) letting, and (2) management.
tabling member printed	Lord Hunt of Kings Heath
uin	HL12611
answer	answer is ministerial correction date of answer 17/01/2019 answer text <p>The Ministry of Defence (MOD) continually seeks to improve its commercial award and management processes. We have established a comprehensive training and education programme under the Commercial Professionalism Programme, which is supported by a robust accreditation process.</p><p>Improving skills and capability will achieve better commercial delivery, which will continue to be measured against the Government commercial operating standards.</p><p>More broadly, contract letting and contract management activities have also been looked at as part of the Government's work to build a new model for delivering outsourced services. The MOD has been actively engaged in this work.</p> answering member printed Earl Howe question first answered 17/01/2019 16:16:20 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath